A Randomized, Observer Blinded, Controlled Trial to Evaluate the Safety and Immunogenicity of a New Formulation of Euvichol (Killed Bivalent Whole Cell Oral Cholera Vaccine Manufactured by EuBiologics Co. Ltd.) in Healthy Individuals

Trial Profile

A Randomized, Observer Blinded, Controlled Trial to Evaluate the Safety and Immunogenicity of a New Formulation of Euvichol (Killed Bivalent Whole Cell Oral Cholera Vaccine Manufactured by EuBiologics Co. Ltd.) in Healthy Individuals

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs Cholera vaccine (Primary) ; Euvichol (Primary)
  • Indications Cholera
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Dec 2015 Planned End Date changed from 1 Apr 2016 to 1 Aug 2016 as per ClinicalTrials.gov record.
    • 16 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.
    • 16 Dec 2015 Planned initiation date changed from 1 Oct 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top